Connect Biopharma Holdings Ltd Cash Flow-to-Debt Ratio
Connect Biopharma Holdings Ltd cash flow-to-debt ratio. Connect Biopharma Holdings Ltd (CNTB) has a Cash Flow-to-Debt Ratio of -1.92x as of June 2026, meaning its operating cash flow of $-31.93 Million could theoretically repay -2% of its total liabilities ($16.61 Million) in one year. Check how high is Connect Biopharma Holdings Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Connect Biopharma Holdings Ltd (2018–2025)
Cash flow-to-debt ratio of Connect Biopharma Holdings Ltd from 2018 to 2025. Historical debt coverage capacity for Connect Biopharma Holdings Ltd across 8 annual periods. Also explore Connect Biopharma Holdings Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Connect Biopharma Holdings Ltd Cash Flow-to-Debt Ratio by Year (2018–2025)
Connect Biopharma Holdings Ltd cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Connect Biopharma Holdings Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of Connect Biopharma Holdings Ltd.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.63x | $-51.21 Million | $14.10 Million | ▼ -40.3% |
| 2024 | -2.59x | $-23.61 Million | $9.12 Million | ▼ -39.8% |
| 2023 | -1.85x | $-47.93 Million | $25.88 Million | ▲ +69.2% |
| 2022 | -6.01x | $-99.27 Million | $16.52 Million | ▲ +79.3% |
| 2021 | -28.99x | $-544.93 Million | $18.80 Million | ▼ -5501.1% |
| 2020 | -0.52x | $-25.61 Million | $49.47 Million | ▲ +45.0% |
| 2019 | -0.94x | $-13.09 Million | $13.91 Million | ▼ -20.9% |
| 2018 | -0.78x | $-69.03 Million | $88.70 Million | — |